SeaStar Medical (ICU) shares are trading higher after the company presented new positive data from the QUELIMMUNE SAVE Registry and revealed insights into the immunomodulatory mechanism of its SCD therapy at the AKI & CRRT 2026 Conference.

Acurx Pharmaceuticals shares are trading higher after the Korean Patent Office granted a new patent for DNA Polymerase IIIC inhibitors, strengthening the company's intellectual property portfolio.

Kezar Life Sciences shares are trading higher after the company announced a definitive merger agreement with Aurinia Pharmaceuticals to be acquired for $6.955 per share in cash, plus a contingent value right.

Quince Therapeutics shares are trading higher after the company announced the successful settlement of its outstanding debt obligations with the European Investment Bank, reducing liabilities by $10.9 million.

Quantum BioPharma shares are trading higher after announcing a strategic partnership with Allucent to conduct a Phase 2 clinical trial for Lucid-MS in treating multiple sclerosis.

Aprea Therapeutics shares are trading higher after the company announced an oversubscribed $30 million private placement led by Soleus Capital, with participation from Vestal Point Capital and Squadron Capital Management.

BullFrog AI shares are trading higher after announcing a commercial agreement with a top 5 global pharmaceutical company to leverage their AI platform in drug discovery for major depressive disorder.

Viridian Therapeutics shares are trading lower despite the company reporting positive topline data from its REVEAL-1 phase 3 clinical trial for elegrobart in thyroid eye disease.

Connect Biopharma shares are trading higher after the company announced that its drug candidate, Rademikibart, demonstrated best-in-class potential in a Phase 3 atopic dermatitis study, with efficacy and safety results presented at the 2026 American Academy of Dermatology Annual Meeting.

United Therapeutics shares are trading higher after the company announced that nebulized Tyvaso achieved significant results in reducing the risk of clinical worsening in idiopathic pulmonary fibrosis patients.

ELAB shares are trading higher after its subsidiary, NorthStrive Biosciences, announced a licensing agreement amendment with MOA Life Plus for dual myostatin assets, aligning development milestones for its EL-22 and EL-32 programs.

Quantum Biopharma shares are trading higher after the company reported robust 2025 financial results, highlighting a strong cash position, reduced liabilities, and advancements in multiple sclerosis and alcohol metabolism drug candidates.

Oxford Industries shares are trading higher after the company initiated fiscal 2026 guidance reflecting improved profitability, driven by momentum at Tommy Bahama. The guidance includes anticipated revenues of $1.475 billion to $1.530 billion and a GAAP EPS of $1.83 to $2.43.

VirTra shares are trading lower after the company reported a 15% decrease in annual revenue and a 45% drop in adjusted EBITDA for 2025, attributed to delays in government funding and customer purchasing cycles.

AmpliTech Group shares are trading lower after the company reported fiscal year results that highlighted significant margin compression despite a 165% increase in revenue, driven by strategic investments in 5G market expansion.

Iridex shares are trading lower after the company reported increasing manufacturing costs and tariff-related challenges impacting gross margins, despite revenue growth in Q4 2025.

Argan shares are trading higher after the company reported record fourth quarter and fiscal year 2026 financial results, with significant increases in revenue, net income, and a robust project backlog exceeding $2.9 billion.

Nortech Systems shares are trading higher after the company reported a significant increase in net income and improved EBITDA for Q4 2025 compared to the previous year.

Glucotrack shares are trading higher after the company announced plans to submit an Investigational Device Exemption (IDE) to the FDA for its novel continuous blood glucose monitoring technology, following successful clinical trials in Brazil and Australia.

Huize Holding shares are trading lower, as investors react negatively despite the company achieving record-breaking insurance premiums and robust revenue growth in 2025, likely due to increased operating costs and reduced net profit in the latter half of the year.